ArticleMicrobial cell factories2026
Mitochondrial and plasma‑membrane transport‑based engineering enables industrial‑level isocitric acid production in Yarrowia lipolytica.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIsocitric acid (ICA) has recently attracted increasing interest because of its nutraceutical relevance and emerging biomedical potential. However, despite its value, industrial exploitation of ICA is still limited owing to the lack of cost‑effective and selective microbial production processes. Mitochondrial transporters play a pivotal role in controlling the pool sizes and fluxes of tricarboxylic acid (TCA) cycle intermediates by mediating their selective exchange across the inner mitochondrial membrane. Recently, we identified the mitochondrial carriers YlYhm2 and YlSfc1 in Yarrowia lipolytica as the specific transporters responsible for citric acid (CA) and ICA efflux, respectively, providing for the first time direct control over the selective secretion of these two organic acids. Building on this discovery, a transporter‑based metabolic engineering strategy was developed to establish a robust and highly selective ICA‑overproducing microbial platform.
resultsStarting from a strain lacking the mitochondrial citrate carrier YlYHM2 and overexpressing the mitochondrial ICA exporter YlSFC1, ICA secretion was further enhanced through overexpression of the plasma‑membrane exporter YlCEX1. To further increase mitochondrial carbon availability feeding the TCA cycle, we overexpressed transporters capable of mediating net carbon import into mitochondria, including the dicarboxylate carriers YlOAC1 and YlDIC1, as well as the pyruvate carrier complex subunits YlMPC1/YlMPC2, either individually or in combination. Among these, YlOAC1 overexpression resulted in the most pronounced improvement, enabling production of 58.4 ± 2.4 g/L ICA with a molar yield of 0.62 mol/mol glucose in shake‑flask cultures. Fed‑batch bioreactor cultivation of this strain under nitrogen‑limited conditions yielded 152.76 ± 3.2 g/L ICA with a process selectivity of 95% (ICA/CA = 20), representing the highest titers and selectivity reported to date for a ICA producer.
conclusionsThese results clearly demonstrate that precise manipulation of mitochondrial and plasma‑membrane transport processes constitutes a powerful and scalable strategy for redirecting carbon flux toward ICA production. This work establishes Y. lipolytica as a robust microbial chassis for industrial ICA manufacturing and highlights selective transport engineering as an effective complementary strategy alongside conventional enzyme centered metabolic engineering approaches, extending and reinforcing previously established roles of mitochondrial carriers in metabolic engineering.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.